Evaluation of Antibody persistence following 4 MenACWY vaccinations

Trial Identifier: 205336
Sponsor: GlaxoSmithKline
Start Date: July 2015
Primary Completion Date: December 2017

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
South Korea Ansan si, South Korea, 425 707
South Korea Incheon, South Korea, 400 711
South Korea Jeonju, South Korea, 561 712
South Korea Seongnam si, South Korea, 463 707
South Korea Seoul, South Korea, 158 710
South Korea Seoul, South Korea, 110 744